Sarah Mac Mullan’s Post

Healthcare is entering a defining moment, with an opportunity to embrace a new wave of innovation. Yet if Europe is to realise the full potential of these breakthroughs, it is vital that people across the region have more timely and equitable access to these treatments.   It is with this potential in mind that I take up a new position on the Board of the European Federation of Pharmaceutical Industries and Associations (EFPIA) – the main body representing the research-based biopharmaceutical industry in Europe.   Alongside my peers from world-leading pharmaceutical companies, I will be working to help deliver on EFPIA’s mission to create an environment that enables our industry to innovate, thrive and deliver new therapies across Europe. At Pfizer, our goal is to change the lives of one billion patients a year by 2027 – but as EFPIA’s mission alludes, this is only possible with the right policy and legislative environment in place.   Europe is often seen as a pharmaceutical powerhouse, with the skilled workforce, academic infrastructure, multi-national institutions, and manufacturing capability making it a location of choice for life science investment. Yet in spite of all this expertise and promise there is still significant inequity in access to new medicines. Patients in Europe are having to wait 517 days for access to innovative treatments on average, ranging from 128 days up to a staggering 1,351 days.* This is an unacceptable situation, and I believe our industry is and should remain an important voice in profiling and remedying this issue. Timely and equitable access is a cause I am deeply passionate about. Through my new role on the EFPIA Board, I am committed to finding and fighting for solutions in partnership with policymakers and stakeholders across Europe, based on a shared understanding of the root causes of unavailability and access delays. This is a real opportunity to create a modernised system that can embrace the next generation of medicines and vaccines. Together, I hope we can achieve a healthier and stronger Europe. * https://lnkd.in/egnbJgvd   #EFPIA #HealthPolicy #LifeSciences #HealthofEurope #MedicineAccess  

Irish Pharma Election Commitments on Innovation and Clinical Trials 💊 As Ireland's biopharmaceutical sector thrives, Shane Ryan, newly appointed President of the Irish Pharmaceutical Healthcare Association (IPHA), calls for continued government investment in innovation and clinical trials ahead of the upcoming general election. Ryan, also General Manager for Takeda Ireland, emphasises the need for strong industry-government partnerships to maintain momentum and improve health outcomes. 🌍 With Ireland's success in pharma, Ryan warns against complacency, urging a long-term focus on fostering an ecosystem that supports innovation in healthcare. 🚀 At Hanley, the emphasis on continued government investment in innovation and clinical trials is essential for the future of Ireland's biopharmaceutical sector. The focus on building strong partnerships between industry and government is key to ensuring ongoing advancements in healthcare. This proactive approach is vital for nurturing an environment that supports innovation and ultimately enhances health outcomes across the region.💼 #IrishPharma #ClinicalTrials #InnovationInHealthcare #IPHA #ShaneRyan #TakedaIreland #HanleyAutomation

IGES Group with HTA experts at BIO-Europe Spring 2024 The IGES Group is once again taking part in BIO-Europe Spring, one of the largest biopharma partnering events in Europe. BIO-Europe Spring 2024 will take place from 18 to 20 March in Barcelona. Up to 3,700 visitors from more than 2,000 companies from the field of innovative biotechnological medicinal products are expected to attend. IGES Group is taking part with experts from the life sciences sector. The aim is to enter into dialogue with researchers, companies and associations about international market access and reimbursement strategies for medical innovations. The focus of this year's discussions is the ongoing HTA harmonisation in Europe, one of the most far-reaching changes in EU pharmaceutical legislation. As EU-HTA stakeholders, companies of IGES Group have been involved in the public consultations on the development of guidelines and guidance documents as part of the EUnetHTA21 activities. IGES France Pharma Consulting will be on site for the first time as a new company of the IGES Group. Founded at the end of 2023, the company specialises in strategic and health economic consulting services for developers and manufacturers of pharmaceuticals who want to launch products on the market in France and Europe. The IGES Group as a whole offers a broad range of research and consulting services for global developers and manufacturers of pharmaceuticals, medical devices and digital health applications. The services support almost all phases of the product life cycle management of new developments. They are focussed on the most important European healthcare markets. #BIOEUROPE #Pharma #Medicines #HTA #IGES

French and German P&MA systems on parallel paths? Explore evolving dynamics and predict the future course of pharmaceutical success in these influential European markets. skp.link/u8t #BetterMarketAccess #Healthcare #Pharma #Pricing #MarketAccess

Britain's pharma industry urges Chancellor to unlock UK life sciences potential 🥼💼 The Association of the British Pharmaceutical Industry (ABPI) has outlined four key areas, in which the new government can unlock the potential of the UK's life science sector. It comes ahead of Chancellor Rachel Reeves' first Labour Budget this month for 14 years. One measure, it suggests, is to deliver a globally competitive regulatory system, which supports innovation and enhances patient access to new medicines. It supports giving the MHRA the resources it needs to do so and also wants to see ring-fenced resourcing for a refreshed and relaunched Innovative Licensing and Access Pathway (ILAP). Continue reading... https://lnkd.in/dvnazYPH #science #technology #innovation #government #pharma #growth #southeast #future #businessnews #businessintelligence

Ireland's pharmaceutical industry launches innovation-focused EU election manifesto Friday's launch of the IPHA's Midlands Northwest manifesto outlines how Ireland's MEPs can play a role in ensuring that EU policies post-election, support the innovation and IP rights they say are required for the development of new medicines, by offering predictability and stability, reducing bureaucracy and showing the European Union is open for investments. Oliver O'Connor, Chief Executive of IPHA, said: "MEPs will have a crucial role to play in advancing the key asks of the pharmaceutical industry in the next mandate of the European Parliament - particularly through the ENVI and ITRE parliamentary committees. Our industry stands ready to play its part and work further with policymakers to ensure a competitive pharmaceutical sector which serves all our patients in Ireland and across Europe." Oliver O'Connor explained that the manifesto was important because: "The pharmaceutical industry has invested heavily in Ireland in recent years, but Europe as a whole has lost a quarter of its global pharmaceutical investment in the last 20 years. This has had a knock-on effect for R&D, innovation and, crucially, patient access to innovative medicines." https://lnkd.in/e5QwX79H #PublicHealth #Europe #StayInformed #StayEmpowered

Study highlights EU's fragmented access to new medicine The W.A.I.T. Indicator is a European study assessing the availability of innovative medicines and the time it takes for patients to access them. "This study highlights the disparity across European countries in the availability of novel medicines, from as little as four months to 2.5 years, showcasing the huge differences experienced by patients in neighbouring countries," said Aurelio Arias, Director of EMEA Thought Leadership at IQVIA, which conducted the study on behalf of the European pharmaceutical association, EFPIA. He told Euractiv: "The number of available medicines has also deteriorated from last year's study, with a drop of 2% in the number of medicines and an increase of 3% in the median time to availability," Arias explained. Bulgaria's bumpy progress Bulgaria provides better access to innovative medicines compared to most countries in Central and Eastern Europe, the W.A.I.T. study reveals. https://lnkd.in/e9wJJJiC #PublicHealth #Europe #StayInformed #StayEmpowered

Today, I had the honour of chairing a panel discussion at the conference we organised on health-related needs as drivers for healthcare policy and innovation.  During the panel discussion, the experts delved into ways of guiding pharmaceutical innovation in order to meet the needs of patients and society within our European healthcare system more effectively. They also discussed the financial landscape of pharmaceutical research and development, identifying obstacles and suggesting tactics to adopt a more needs-driven approach. This conference marks another crucial step ahead as we keep working together on this very important topic.

🌟 Wrapping Up the Week: Reflecting on Morocco's Impact in Pharma and Clinical Research 🌟 As we close another productive week, it's worth highlighting Morocco's expanding influence in the pharmaceutical and clinical research sectors. The nation is quickly establishing itself as a go-to destination for multinational pharmaceutical companies, thanks to its strategic positioning, cost-effectiveness, and advanced infrastructure. Clinova has been closely monitoring Morocco's growing stature as an ideal location for clinical trials. The country's engagement with international regulatory entities, like the FDA, mirrors our commitment to uphold global standards in clinical research. This past year marked a significant milestone with the Moroccan Directorate of Medicines and Pharmacy becoming an independent entity. This transition is part of Morocco’s broader strategy to evolve into a central hub for quality medical manufacturing and clinical research, elevating its role as a key player on the global healthcare stage. As the week concludes, we at Clinova are excited about the possibilities ahead. Morocco's healthcare evolution presents vast opportunities for collaborative clinical trials, allowing us to contribute to medical research and patient care on a global scale. Here’s to a future of continued innovation and partnership! Wishing everyone a restful and rejuvenating weekend. #ClinicalResearch #Pharmaceuticals #FDA #Morocco #Clinova #GlobalHealthcare #EndOfTheWeekReflection #ClinicalTrials

Calls for less bureaucracy, more cooperation to promote EU pharmaceutical competitiveness: The EU must foster life sciences collaboration and bold action, it's at a turning point where the problems of competitiveness have been diagnosed, and now those problems must be addressed. The post Calls for less bureaucracy, more cooperation to promote EU pharmaceutical competitiveness appeared first on Euractiv.